Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development

Adenosine receptors (ARs) function in the body's response to conditions of pathology and stress associated with a functional imbalance, such as in the supply and demand of energy/oxygen/nutrients. Extracellular adenosine concentrations vary widely to raise or lower the basal activation of four...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cellular neuroscience Vol. 13; p. 124
Main Authors Jacobson, Kenneth A., Tosh, Dilip K., Jain, Shanu, Gao, Zhan-Guo
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Research Foundation 28.03.2019
Frontiers Media S.A
Subjects
Adenosine
Adenosine receptors
Agonists
Allosteric properties
Angina
Antagonists
Cardiac muscle
Clinical trials
CNS
Diabetes
Diabetes mellitus
Gene expression
Heart
Heart rate
Hypoxia
inflammation
Ischemia
Kinases
Neuroscience
Nutrients
Pain
purinergic signaling
Receptor mechanisms
Sickle cell disease
CNS
pain
purinergic signaling
inflammation
adenosine receptors
Online AccessGet full text
ISSN1662-5102
1662-5102
DOI10.3389/fncel.2019.00124

Cover

Abstract Adenosine receptors (ARs) function in the body's response to conditions of pathology and stress associated with a functional imbalance, such as in the supply and demand of energy/oxygen/nutrients. Extracellular adenosine concentrations vary widely to raise or lower the basal activation of four subtypes of ARs. Endogenous adenosine can correct an energy imbalance during hypoxia and other stress, for example, by slowing the heart rate by A AR activation or increasing the blood supply to heart muscle by the A AR. Moreover, exogenous AR agonists, antagonists, or allosteric modulators can be applied for therapeutic benefit, and medicinal chemists working toward that goal have reported thousands of such agents. Thus, numerous clinical trials have ensued, using promising agents to modulate adenosinergic signaling, most of which have not succeeded. Currently, short-acting, parenteral agonists, adenosine and Regadenoson, are the only AR agonists approved for human use. However, new concepts and compounds are currently being developed and applied toward preclinical and clinical evaluation, and initial results are encouraging. This review focuses on key compounds as AR agonists and positive allosteric modulators (PAMs) for disease treatment or diagnosis. AR agonists for treating inflammation, pain, cancer, non-alcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions and diabetes have been under development. Multiple clinical trials with two A AR agonists are ongoing.
AbstractList Adenosine receptors (ARs) function in the body’s response to conditions of pathology and stress associated with a functional imbalance, such as in the supply and demand of energy/oxygen/nutrients. Extracellular adenosine concentrations vary widely to raise or lower the basal activation of four subtypes of ARs. Endogenous adenosine can correct an energy imbalance during hypoxia and other stress, for example, by slowing the heart rate by A1AR activation or increasing the blood supply to heart muscle by the A2AAR. Moreover, exogenous AR agonists, antagonists, or allosteric modulators can be applied for therapeutic benefit, and medicinal chemists working toward that goal have reported thousands of such agents. Thus, numerous clinical trials have ensued, using promising agents to modulate adenosinergic signaling, most of which have not succeeded. Currently, short-acting, parenteral agonists, adenosine and Regadenoson, are the only AR agonists approved for human use. However, new concepts and compounds are currently being developed and applied toward preclinical and clinical evaluation, and initial results are encouraging. This review focuses on key compounds as AR agonists and positive allosteric modulators (PAMs) for disease treatment or diagnosis. AR agonists for treating inflammation, pain, cancer, non-alcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions and diabetes have been under development. Multiple clinical trials with two A3AR agonists are ongoing.
Adenosine receptors (ARs) function in the body’s response to conditions of pathology and stress associated with a functional imbalance, such as in the supply and demand of energy/oxygen/nutrients. Extracellular adenosine concentrations vary widely to raise or lower the basal activation of four subtypes of ARs. Endogenous adenosine can correct an energy imbalance during hypoxia and other stress, for example, by slowing the heart rate by A 1 AR activation or increasing the blood supply to heart muscle by the A 2A AR. Moreover, exogenous AR agonists, antagonists, or allosteric modulators can be applied for therapeutic benefit, and medicinal chemists working toward that goal have reported thousands of such agents. Thus, numerous clinical trials have ensued, using promising agents to modulate adenosinergic signaling, most of which have not succeeded. Currently, short-acting, parenteral agonists, adenosine and Regadenoson, are the only AR agonists approved for human use. However, new concepts and compounds are currently being developed and applied toward preclinical and clinical evaluation, and initial results are encouraging. This review focuses on key compounds as AR agonists and positive allosteric modulators (PAMs) for disease treatment or diagnosis. AR agonists for treating inflammation, pain, cancer, non-alcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions and diabetes have been under development. Multiple clinical trials with two A 3 AR agonists are ongoing.
Adenosine receptors (ARs) function in the body’s response to conditions of pathology and stress associated with a functional imbalance, such as in the supply and demand of energy/oxygen/nutrients. Extracellular adenosine concentrations vary widely to raise or lower the basal activation of four subtypes of ARs. Endogenous adenosine can correct an energy imbalance during hypoxia and other stress, for example, by slowing the heart rate by A1AR activation or increasing the blood supply to heart muscle by the A2AAR. Moreover, exogenous AR agonists, antagonists, or allosteric modulators can be applied for therapeutic benefit, and medicinal chemists working toward that goal have reported thousands of such agents. Thus, numerous clinical trials have ensued, using promising agents to modulate adenosinergic signaling, most of which have not succeeded. Currently, short-acting, parenteral agonists, adenosine and Regadenoson, are the only AR agonists approved for human use. However, new concepts and compounds are currently being developed and applied toward preclinical and clinical evaluation, and initial results are encouraging. This review focuses on key compounds as AR agonists and positive allosteric modulators (PAMs) for disease treatment or diagnosis. AR agonists for treating inflammation, pain, cancer, nonalcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions and diabetes have been under development. Multiple clinical trials with two A3AR agonists are ongoing
Adenosine receptors (ARs) function in the body's response to conditions of pathology and stress associated with a functional imbalance, such as in the supply and demand of energy/oxygen/nutrients. Extracellular adenosine concentrations vary widely to raise or lower the basal activation of four subtypes of ARs. Endogenous adenosine can correct an energy imbalance during hypoxia and other stress, for example, by slowing the heart rate by A AR activation or increasing the blood supply to heart muscle by the A AR. Moreover, exogenous AR agonists, antagonists, or allosteric modulators can be applied for therapeutic benefit, and medicinal chemists working toward that goal have reported thousands of such agents. Thus, numerous clinical trials have ensued, using promising agents to modulate adenosinergic signaling, most of which have not succeeded. Currently, short-acting, parenteral agonists, adenosine and Regadenoson, are the only AR agonists approved for human use. However, new concepts and compounds are currently being developed and applied toward preclinical and clinical evaluation, and initial results are encouraging. This review focuses on key compounds as AR agonists and positive allosteric modulators (PAMs) for disease treatment or diagnosis. AR agonists for treating inflammation, pain, cancer, non-alcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions and diabetes have been under development. Multiple clinical trials with two A AR agonists are ongoing.
Adenosine receptors (ARs) function in the body's response to conditions of pathology and stress associated with a functional imbalance, such as in the supply and demand of energy/oxygen/nutrients. Extracellular adenosine concentrations vary widely to raise or lower the basal activation of four subtypes of ARs. Endogenous adenosine can correct an energy imbalance during hypoxia and other stress, for example, by slowing the heart rate by A1AR activation or increasing the blood supply to heart muscle by the A2AAR. Moreover, exogenous AR agonists, antagonists, or allosteric modulators can be applied for therapeutic benefit, and medicinal chemists working toward that goal have reported thousands of such agents. Thus, numerous clinical trials have ensued, using promising agents to modulate adenosinergic signaling, most of which have not succeeded. Currently, short-acting, parenteral agonists, adenosine and Regadenoson, are the only AR agonists approved for human use. However, new concepts and compounds are currently being developed and applied toward preclinical and clinical evaluation, and initial results are encouraging. This review focuses on key compounds as AR agonists and positive allosteric modulators (PAMs) for disease treatment or diagnosis. AR agonists for treating inflammation, pain, cancer, non-alcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions and diabetes have been under development. Multiple clinical trials with two A3AR agonists are ongoing.Adenosine receptors (ARs) function in the body's response to conditions of pathology and stress associated with a functional imbalance, such as in the supply and demand of energy/oxygen/nutrients. Extracellular adenosine concentrations vary widely to raise or lower the basal activation of four subtypes of ARs. Endogenous adenosine can correct an energy imbalance during hypoxia and other stress, for example, by slowing the heart rate by A1AR activation or increasing the blood supply to heart muscle by the A2AAR. Moreover, exogenous AR agonists, antagonists, or allosteric modulators can be applied for therapeutic benefit, and medicinal chemists working toward that goal have reported thousands of such agents. Thus, numerous clinical trials have ensued, using promising agents to modulate adenosinergic signaling, most of which have not succeeded. Currently, short-acting, parenteral agonists, adenosine and Regadenoson, are the only AR agonists approved for human use. However, new concepts and compounds are currently being developed and applied toward preclinical and clinical evaluation, and initial results are encouraging. This review focuses on key compounds as AR agonists and positive allosteric modulators (PAMs) for disease treatment or diagnosis. AR agonists for treating inflammation, pain, cancer, non-alcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions and diabetes have been under development. Multiple clinical trials with two A3AR agonists are ongoing.
Author Gao, Zhan-Guo
Jacobson, Kenneth A.
Jain, Shanu
Tosh, Dilip K.
AuthorAffiliation Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD , United States
AuthorAffiliation_xml – name: Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD , United States
Author_xml – sequence: 1
  givenname: Kenneth A.
  surname: Jacobson
  fullname: Jacobson, Kenneth A.
– sequence: 2
  givenname: Dilip K.
  surname: Tosh
  fullname: Tosh, Dilip K.
– sequence: 3
  givenname: Shanu
  surname: Jain
  fullname: Jain, Shanu
– sequence: 4
  givenname: Zhan-Guo
  surname: Gao
  fullname: Gao, Zhan-Guo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30983976$$D View this record in MEDLINE/PubMed
BookMark eNp1kktvEzEUhS3Uij5gzwqNxIZNgp93ZjZIUWhppUpFCDZsrBvbExxN7GDPVOq_r5M00FZi5dd3ju-1zxk5CjE4Qt4xOhWiaT91wbh-yilrp5QyLl-RUwbAJ4pRfvRkfkLOcl5RChxk85qcCNo2oq3hlPy68nmIyRvsKwy2mo8puTBUM-tCzD646rszblOQaraMocC58qH6lpzpffgnOyy-uDvXx826eLwhxx322b19HM_Jz8uLH_Oryc3t1-v57GZilIJhIqHmQBW3dctYWzuOprRigRmOqpYLCcrUjegUbxgKyjvVLoCahlO7cB104pxc731txJXeJL_GdK8jer3biGmpMQ3e9E4bBCuEs6IRKC0qRCg3cOxQWeC8KV6f916bcbF21pQ2EvbPTJ-fBP9bL-OdBilrYKwYfHw0SPHP6PKg1z6XT-oxuDhmzTmjlEoJW_TDC3QVxxTKUxWq4YpBYQv1_mlFf0s5fGEBYA-YFHNOrtPGDzj4uC3Q95pRvc2K3mVFb7Oid1kpQvpCePD-r-QBIprCAQ
CitedBy_id crossref_primary_10_3390_cells11071094
crossref_primary_10_3389_fimmu_2021_613070
crossref_primary_10_1016_j_neulet_2023_137413
crossref_primary_10_1128_IAI_00653_20
crossref_primary_10_1021_acsmedchemlett_1c00598
crossref_primary_10_1111_cbdd_14128
crossref_primary_10_1016_j_neuropharm_2020_108213
crossref_primary_10_1096_fj_202002658RR
crossref_primary_10_1093_cvr_cvaa275
crossref_primary_10_1007_s00044_022_02908_9
crossref_primary_10_1016_j_cub_2024_11_006
crossref_primary_10_1177_20406223221140392
crossref_primary_10_3390_ijms22157952
crossref_primary_10_1016_j_expneurol_2024_114930
crossref_primary_10_1038_s41467_024_53473_1
crossref_primary_10_1038_s41388_021_02090_z
crossref_primary_10_1016_j_tox_2021_152909
crossref_primary_10_1016_j_jid_2022_07_032
crossref_primary_10_3389_fimmu_2022_912279
crossref_primary_10_1016_j_biopha_2023_115184
crossref_primary_10_1016_j_tcb_2021_05_008
crossref_primary_10_3389_fphar_2021_649807
crossref_primary_10_3390_ijms25136959
crossref_primary_10_1080_07391102_2020_1828172
crossref_primary_10_1021_acs_jmedchem_0c00564
crossref_primary_10_3390_ijms25126534
crossref_primary_10_3389_fimmu_2022_904762
crossref_primary_10_3390_biomedicines10020515
crossref_primary_10_1111_bph_16468
crossref_primary_10_1016_j_pbb_2021_173194
crossref_primary_10_1124_pharmrev_121_000445
crossref_primary_10_3390_molecules27072283
crossref_primary_10_1111_bph_17319
crossref_primary_10_1002_cmdc_202000465
crossref_primary_10_1177_1536012120927609
crossref_primary_10_3390_ijms20235964
crossref_primary_10_1021_acsmedchemlett_3c00315
crossref_primary_10_18097_pbmc20236906353
crossref_primary_10_1021_acs_jmedchem_1c01636
crossref_primary_10_3390_biom10060812
crossref_primary_10_3390_ph12040150
crossref_primary_10_3389_fphar_2022_1030895
crossref_primary_10_3389_fphar_2021_652121
crossref_primary_10_1186_s10194_022_01412_0
crossref_primary_10_1007_s11302_022_09851_9
crossref_primary_10_1021_acschembio_0c00899
crossref_primary_10_3390_ijms21228512
crossref_primary_10_3389_fimmu_2020_604944
crossref_primary_10_1016_j_bcp_2020_114300
crossref_primary_10_1002_jcp_30594
crossref_primary_10_1111_bph_16099
crossref_primary_10_1038_s41392_023_01652_9
crossref_primary_10_2174_0113816128266227231205114320
crossref_primary_10_1021_acs_jmedchem_2c01170
crossref_primary_10_1161_HYPERTENSIONAHA_123_20582
crossref_primary_10_3390_molecules27030707
crossref_primary_10_3390_molecules27061890
crossref_primary_10_1016_j_lssr_2022_07_004
crossref_primary_10_3389_fphar_2021_672182
crossref_primary_10_1007_s11302_023_09924_3
crossref_primary_10_1039_D1MD00167A
crossref_primary_10_3390_biomedicines8110461
crossref_primary_10_3389_fmed_2021_733080
crossref_primary_10_3389_fendo_2021_718429
crossref_primary_10_1097_ALN_0000000000003788
crossref_primary_10_3389_fphar_2020_627838
crossref_primary_10_1371_journal_pone_0239692
crossref_primary_10_1021_acs_bioconjchem_1c00387
crossref_primary_10_1177_03331024221077665
crossref_primary_10_1016_j_bcp_2020_114311
crossref_primary_10_3389_fphar_2021_724320
crossref_primary_10_3389_fendo_2023_1184360
crossref_primary_10_3904_kjim_2021_093
crossref_primary_10_3390_molecules25010130
crossref_primary_10_3390_molecules26175384
crossref_primary_10_1097_j_pain_0000000000002804
crossref_primary_10_1016_j_bcp_2020_114393
crossref_primary_10_3389_fimmu_2022_866097
crossref_primary_10_3390_receptors2010004
crossref_primary_10_1016_j_neuropharm_2023_109503
crossref_primary_10_1016_j_cellsig_2021_109954
crossref_primary_10_1111_bph_15103
crossref_primary_10_1186_s40478_022_01315_w
crossref_primary_10_3390_jcm9093045
crossref_primary_10_1016_j_celrep_2022_110727
crossref_primary_10_1016_j_biopha_2022_113408
crossref_primary_10_1016_j_ejmech_2021_113907
crossref_primary_10_1111_febs_15800
crossref_primary_10_1089_caff_2019_0024
crossref_primary_10_3390_cells9051200
crossref_primary_10_1002_ame2_12458
crossref_primary_10_3390_biomedicines9020204
crossref_primary_10_1007_s00044_021_02704_x
crossref_primary_10_1021_acs_jcim_2c01181
crossref_primary_10_1080_14756366_2020_1862103
crossref_primary_10_3390_ijms24054404
crossref_primary_10_1097_j_pain_0000000000002999
crossref_primary_10_1007_s11302_022_09873_3
crossref_primary_10_3390_biom13091387
crossref_primary_10_1161_HYPERTENSIONAHA_124_21726
crossref_primary_10_3390_cells10123560
crossref_primary_10_1038_s42003_023_04727_z
crossref_primary_10_1016_j_jgg_2022_01_006
crossref_primary_10_3389_fcvm_2019_00194
crossref_primary_10_3389_fphar_2020_621955
crossref_primary_10_3389_fphar_2020_609849
crossref_primary_10_1007_s11302_020_09717_y
crossref_primary_10_1021_jacs_3c08428
crossref_primary_10_1016_j_ejmech_2022_114103
crossref_primary_10_3390_molecules26041188
crossref_primary_10_1021_acs_jmedchem_9b01164
crossref_primary_10_1097_j_pain_0000000000001857
crossref_primary_10_1111_bph_15252
crossref_primary_10_1007_s11302_024_09992_z
crossref_primary_10_1111_acel_13218
crossref_primary_10_3389_fendo_2020_00329
crossref_primary_10_1007_s10787_023_01421_8
crossref_primary_10_1007_s12262_020_02272_1
crossref_primary_10_1021_acs_jpcb_4c07391
crossref_primary_10_1021_acs_jmedchem_2c01414
crossref_primary_10_3390_ijms21124547
crossref_primary_10_3390_ijms21228710
crossref_primary_10_3389_fphar_2022_920643
crossref_primary_10_1007_s11154_021_09668_8
crossref_primary_10_1021_acs_jmedchem_0c01431
crossref_primary_10_3390_cells9030785
crossref_primary_10_1021_acs_jmedchem_4c00944
crossref_primary_10_1039_D1RA00363A
crossref_primary_10_1161_HYPERTENSIONAHA_119_13698
crossref_primary_10_1016_j_yexmp_2025_104952
crossref_primary_10_1186_s12974_020_02009_7
crossref_primary_10_1016_j_bbi_2020_07_026
crossref_primary_10_1016_j_ynpai_2022_100087
crossref_primary_10_1016_j_ejmech_2023_115691
crossref_primary_10_1021_acs_accounts_5c00011
crossref_primary_10_1007_s00210_023_02617_z
crossref_primary_10_1021_acschemneuro_1c00397
crossref_primary_10_3389_fonc_2021_636373
crossref_primary_10_1016_j_phrs_2020_105253
crossref_primary_10_3390_molecules27072184
crossref_primary_10_3390_ijms21207470
Cites_doi 10.1126/science.1202793
10.1124/mol.52.5.846
10.1164/rccm.201506-1253OC
10.3389/fphar.2018.00310
10.1111/j.1467-2494.2006.00349.x
10.3390/ijms20030528
10.1016/j.neuropharm.2014.01.028
10.1002/cmdc.201700151
10.1097/CRD.0b013e3182613db6
10.3389/fchem.2016.00037
10.1007/978-3-319-90808-3_20
10.1038/bjp.2008.329
10.2337/db13-0573
10.1002/jcph.828
10.1517/13543784.2015.1099627
10.3389/fphar.2017.00878
10.1007/978-3-540-89615-9_2
10.1016/j.bcp.2017.03.014
10.1016/j.ejps.2004.09.010
10.1021/jm501021n
10.1038/s41586-018-0236-6
10.1371/journal.pone.0202914
10.1002/ddr.10197
10.1634/theoncologist.2012-0211
10.1016/j.cell.2017.12.004
10.1016/j.jpain.2003.10.001
10.1021/jm0003642
10.1161/CIRCULATIONAHA.117.028087
10.1021/acs.jmedchem.8b01009
10.1124/mol.116.105551
10.1182/bloodadvances.2017009613
10.1097/ALN.0b013e3181b060f2
10.1177/00912700122009845
10.1016/j.bcp.2018.02.002
10.1586/ecp.09.57
10.1155/2015/585297
10.1124/mol.115.099499
10.1007/978-3-319-90808-3_5
10.1371/journal.pbio.3000161
10.1007/s11302-011-9268-1
10.1002/med.21432
10.1161/01.CIR.99.8.1034
10.4049/jimmunol.0903617
10.1016/j.bcp.2014.05.008
10.3389/fphar.2017.00947
10.1038/s41598-018-35266-x
10.2174/1381612820666141029100346
10.1016/j.neuropharm.2016.11.026
10.3389/fphar.2017.00224
10.1007/s00259-018-4120-2
10.1371/journal.pone.0098775
10.1016/j.juro.2016.02.2465
10.1016/j.tips.2016.02.006
10.1155/2018/2310970
10.1039/9781782629276
10.1124/jpet.115.229872
10.1161/CIRCIMAGING.108.817932
10.3390/md16010006
10.1016/j.neuropharm.2016.09.015
10.1089/jop.2016.0090
10.1016/j.jelectrocard.2015.08.010
10.1161/CIRCULATIONAHA.111.057596
10.3389/fphar.2018.00506
10.1007/s11302-011-9274-3
10.1152/physrev.00049.2017
10.1007/s11302-014-9409-4
10.1093/brain/awu330
10.1038/nri.2016.4
10.1007/s11302-015-9459-2
10.1002/jcp.25043
10.1021/jm00031a014
10.1172/JCI76207
10.1016/j.bcp.2019.01.022
10.1096/fj.11-201541
10.1111/j.1747-0803.2012.00669.x
10.1016/j.bbamem.2010.06.007
10.1023/A:1014417728325
10.1016/j.bcp.2011.06.017
10.1097/00005344-199703000-00017
10.1161/CIRCEP.109.884429
10.1021/acschemneuro.5b00056
10.1016/S0304-3959(03)00158-1
10.1111/bph.14337
10.1016/j.molmed.2010.12.006
10.1021/jm960682u
10.1007/164_2016_83
10.1016/j.bcp.2015.07.007
10.1038/nature10136
10.1007/s11302-015-9450-y
10.1007/s12350-011-9474-9
10.1016/j.expneurol.2009.05.018
10.1155/2014/708746
10.1097/j.pain.0000000000001488
10.1093/eurheartj/ehy301
10.1378/chest.128.4.1905
10.1097/j.pain.0000000000001177
10.1111/bph.13763
10.2147/DDDT.S195294
10.1093/eurheartj/ehq039
10.1016/j.bcp.2017.12.003
10.1002/jcph.9
10.1016/S0165-1838(00)00106-5
10.1021/acs.jmedchem.8b01662
10.1016/j.neuron.2015.07.010
10.1016/j.joa.2017.02.002
10.1517/13543780802497284
10.1126/science.1132559
10.1007/s11302-014-9427-2
10.1016/j.ajpath.2011.07.006
10.1021/jm0255724
10.1517/13543776.2013.799142
10.1016/j.mam.2016.12.001
10.1016/S0006-2952(03)00153-9
10.1152/ajpheart.00819.2007
10.1016/j.nucmedbio.2008.10.003
10.1007/978-90-481-3144-0_1
10.3390/molecules171213712
10.1111/imr.12528
10.1007/s00392-012-0430-8
10.1124/pr.112.006361
10.1111/bph.13446
10.1021/jm300965a
10.1007/s11302-015-9460-9
10.1084/jem.20030891
10.1016/j.drudis.2011.10.007
10.1016/S0168-8227(97)00116-2
10.1007/s11302-017-9592-1
10.1002/med.21456
10.1016/j.chest.2016.06.045
10.1016/j.neuropharm.2018.02.035
10.1007/s10741-015-9522-7
10.1016/S0014-2999(97)01605-1
10.1038/nrd3955
10.1002/dmrr.2446
10.7554/eLife.35946
10.1038/nrd1983
10.1016/j.hoc.2013.11.003
10.1021/jm050726b
10.1016/j.alit.2016.10.001
10.1371/journal.pmed.0050137
10.1089/jop.2015.0148
10.1038/nrrheum.2016.178
10.2147/COPD.S56879
10.1023/A:1023601007518
10.1097/00045391-200405000-00005
10.1182/blood.V116.21.2990.2990
10.1016/S0168-8278(18)30921-8
10.1038/nrendo.2015.10
10.1371/journal.pone.0173518
10.1016/j.ophtha.2009.11.029
10.1007/s10753-015-0184-3
10.1016/S0014-2999(98)00977-7
10.1186/s12987-017-0088-8
10.1016/j.jss.2018.06.042
ContentType Journal Article
Copyright 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2019 Jacobson, Tosh, Jain and Gao. 2019 Jacobson, Tosh, Jain and Gao
Copyright_xml – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2019 Jacobson, Tosh, Jain and Gao. 2019 Jacobson, Tosh, Jain and Gao
DBID AAYXX
CITATION
NPM
3V.
7XB
88I
8FE
8FH
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M2P
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3389/fncel.2019.00124
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest : Biological Science Collection journals [unlimited simultaneous users]
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Open Access Full Text
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1662-5102
ExternalDocumentID oai_doaj_org_article_ca6d33ed383a4da5aa674b2afa5d6228
PMC6447611
30983976
10_3389_fncel_2019_00124
Genre Journal Article
Review
GrantInformation_xml – fundername: Intramural NIH HHS
  grantid: ZIA DK031117
– fundername: National Institute of Diabetes and Digestive and Kidney Diseases
  grantid: ZIA DK031117
GroupedDBID ---
29H
2WC
53G
5GY
5VS
88I
8FE
8FH
9T4
AAFWJ
AAYXX
ABUWG
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AEGXH
AENEX
AFKRA
AFPKN
AIAGR
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
CS3
DIK
DWQXO
E3Z
EMOBN
F5P
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HYE
KQ8
LK8
M2P
M48
M7P
M~E
O5R
O5S
OK1
OVT
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
TR2
C1A
IPNFZ
NPM
PQGLB
RIG
3V.
7XB
8FK
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c556t-46726052d791197e2ac012d61c2a574b465c783f5281a302f59b60c820dbef6f3
IEDL.DBID M48
ISSN 1662-5102
IngestDate Wed Aug 27 01:31:38 EDT 2025
Thu Aug 21 18:22:57 EDT 2025
Thu Jul 10 17:40:30 EDT 2025
Fri Jul 25 11:47:53 EDT 2025
Mon Jul 21 06:02:42 EDT 2025
Thu Apr 24 22:51:20 EDT 2025
Tue Jul 01 03:30:13 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords CNS
pain
purinergic signaling
inflammation
adenosine receptors
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c556t-46726052d791197e2ac012d61c2a574b465c783f5281a302f59b60c820dbef6f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Reviewed by: Sergi Ferre, Intramural Research Program (NIDA), United States; Francisco Ciruela, University of Barcelona, Spain; Patrizia Popoli, Istituto Superiore di Sanità (ISS), Italy
Edited by: David Blum, INSERM U1172 Centre de Recherche Jean-Pierre Aubert, France
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fncel.2019.00124
PMID 30983976
PQID 2282516210
PQPubID 4424410
ParticipantIDs doaj_primary_oai_doaj_org_article_ca6d33ed383a4da5aa674b2afa5d6228
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6447611
proquest_miscellaneous_2210004461
proquest_journals_2282516210
pubmed_primary_30983976
crossref_citationtrail_10_3389_fncel_2019_00124
crossref_primary_10_3389_fncel_2019_00124
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-03-28
PublicationDateYYYYMMDD 2019-03-28
PublicationDate_xml – month: 03
  year: 2019
  text: 2019-03-28
  day: 28
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Lausanne
PublicationTitle Frontiers in cellular neuroscience
PublicationTitleAlternate Front Cell Neurosci
PublicationYear 2019
Publisher Frontiers Research Foundation
Frontiers Media S.A
Publisher_xml – name: Frontiers Research Foundation
– name: Frontiers Media S.A
References Jacobson (B85) 2006; 5
Eisenach (B45) 2004; 5
Fedorova (B53) 2003; 23
Baltos (B10) 2017; 135
Cohen (B33) 2016; 195
Fishman (B57) 2018; 68
Janes (B90) 2016; 173
Wojcik (B162) 2014; 30
Bigot (B14) 2004
Borea (B17) 2017; 174
Luongo (B109) 2012; 17
Zoghbi (B167) 2012; 19
Gao (B64) 2003; 65
Knezevic (B97) 2015; 24
Mason (B111) 2009; 2
García-Nafría (B69) 2018; 7
Leung (B107) 2014; 10
Olsson (B121) 2003; 58
Xu (B164) 2011; 332
Borea (B18) 2018; 98
Cheng (B27) 2000; 83
Avni (B9) 2010; 117
Jacobson (B87) 2005; 48
Auchampach (B8) 1997; 52
Rieger (B128) 2001; 44
Fishman (B56) 2012; 17
Wilbrandt (B161) 1972; 67
David (B39) 2016; 15
Rapaport (B126) 2015; 11
Eltzschig (B49) 2003; 198
Pelleg (B124) 2012; 8
Choi (B28) 2011; 179
Gao (B67) 2011; 82
Flyer (B58) 2017; 135
Victor-Vega (B153) 2002; 26
Cohen (B32) 2019; 13
Carlin (B22) 2016; 356
Dinh (B41) 2017; 243
Eltzschig (B48) 2009; 111
Trevethick (B149) 2008; 155
Basoglu (B13) 2005; 128
Greene (B73) 2016; 21
Lam (B103) 2018; 39
Eisenstein (B47) 2015; 230
Meibom (B112) 2017; 12
Squadrito (B136) 2017; 8
Du (B43) 2018; 14
Serchov (B133) 2015; 87
Isogai (B82) 2017; 66
Myers (B117) 2016; 32
Miao (B113) 2018; 8
Faghihi (B51) 2013; 21
Jin (B91) 2017; 12
Albrecht-Küpper (B2) 2012; 8
Golzar (B72) 2014; 9
Imlach (B79) 2015; 88
Pelleg (B125) 2016; 150
Jackson (B83) 2018; 15
Kim (B96) 2016; 126
DeNinno (B40) 2003; 46
Jacobson (B89) 2018; 38
Ning (B120) 2011
Haskó (B77) 2018; 151
Gallo-Rodriguez (B62) 1994; 37
Cox (B36) 1997; 29
Tozzi (B148) 2017; 8
Lahesmaa (B102) 2018; 46
Fozard (B59) 2010
Szentmiklosi (B140) 2015; 21
Lasley (B104) 2018; 9
Tosh (B144) 2014; 57
Eisenach (B46) 2013; 105
Van der Graaf (B150) 1999; 290
Burnstock (B19) 2014; 10
Gao (B65) 2018; 151
Schaddelee (B130) 2005; 24
Tian (B143) 2015; 2015
Voors (B157) 2017; 57
Johnston-Cox (B93) 2014; 9
Boison (B15) 2013; 65
Guo (B75) 2018; 61
Knutsen (B98) 1999; 42
Szybala (B141) 2009; 219
García (B68) 2018; 16
Jacobson (B86) 2017
Vuerich (B158) 2019; 20
Fredholm (B60) 2001; 53
Coppi (B34) 2019
Csóka (B38) 2014; 63
Carlin (B21) 2017; 114
Jacobson (B84) 2016; 32
Vincenzi (B155) 2014; 82
Allard (B3) 2017; 276
Mundell (B115) 2011; 1808
Schaumann (B131) 1972; 22
Corino (B35) 2015; 48
Lebon (B105) 2011; 474
Bar-Yehuda (B12) 2008; 33
Tosh (B146) 2012; 55
Staehr (B137) 2013; 53
Stemmer (B138) 2013; 18
Tosh (B145) 2015; 11
Wan (B160) 2019; 163
Abella (B1) 2006; 28
Cekic (B23) 2016; 16
Koussémou (B101) 2018; 13
Montesinos (B114) 2015; 38
Cronstein (B37) 2017; 13
Galiuto (B61) 2010; 31
Giorgi (B70) 2013; 23
Hart (B76) 2011; 186
Palani (B122) 2013; 21
Sharma (B135) 2016; 193
Grenz (B74) 2008; 5
Mantell (B110) 2010; 3
Alnouri (B5) 2015; 11
Kiesman (B95) 2009; 193
Eddy (B44) 2018; 172
Fang (B52) 2015; 97
Draper-Joyce (B42) 2018; 558
Letsas (B106) 2017; 33
Zannikos (B165) 2001; 41
Koupenova (B100) 2012; 125
Jacobson (B88) 2001; 151
Chen (B25) 2006; 314
Little (B108) 2015; 138
Antonioli (B6) 2015; 11
Sawynok (B129) 1998; 347
van Waarde (B151) 2018; 38
Zylka (B168) 2011; 17
Peleli (B123) 2017; 55
Kiesewetter (B94) 2009; 36
Cohen (B30) 2014; 2014
Tosh (B147) 2019; 62
Korinek (B99) 2018
Chen (B26) 2012; 26
Sun (B139) 2016; 4
Vincenzi (B154) 2016; 111
Xiao (B163) 2019; 17
Elzein (B50) 2008; 17
Tendera (B142) 2012; 101
Baraldi (B11) 2018
Cohen (B31) 2018; 2018
Rickles (B127) 2010; 116
Field (B55) 2014; 28
Shah (B134) 2004; 11
Hothersall (B78) 2017; 91
Chen (B24) 2013; 12
von Lubitz (B156) 1999; 367
Ishikawa (B81) 1998; 39
Nascimento (B118) 2012
Field (B54) 2017; 1
Murray (B116) 2009; 2
Zheng (B166) 2007; 293
Antonioli (B7) 2018
Schaumann (B132) 1972; 22
Wahlman (B159) 2018; 159
Allen (B4) 2013
Vecchio (B152) 2018; 175
Jinka (B92) 2015; 6
Gao (B66) 2017; 8
Gao (B63) 2014; 90
Ni (B119) 2018; 232
Glatter (B71) 1999; 99
Borea (B16) 2016; 37
Carlin (B20) 2018; 139
Chrysostomou (B29) 2013; 8
Irrera (B80) 2018; 9
References_xml – volume: 332
  start-page: 322
  year: 2011
  ident: B164
  article-title: Structure of an agonist-bound human A2A adenosine receptor.
  publication-title: Science
  doi: 10.1126/science.1202793
– volume: 52
  start-page: 846
  year: 1997
  ident: B8
  article-title: Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor.
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.52.5.846
– volume: 193
  start-page: 988
  year: 2016
  ident: B135
  article-title: NOX2 activation of natural killer T cells is blocked by the adenosine A2A receptor to inhibit lung ischemia-reperfusion injury.
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.201506-1253OC
– volume: 9
  year: 2018
  ident: B104
  article-title: Adenosine receptor-mediated cardioprotection - current limitations and future directions.
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2018.00310
– volume: 290
  start-page: 702
  year: 1999
  ident: B150
  article-title: Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A1 receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 28
  start-page: 447
  year: 2006
  ident: B1
  article-title: Evaluation of anti-wrinkle efficacy of adenosine-containing products using the FOITS technique.
  publication-title: Int. J. Cosmetic Sci.
  doi: 10.1111/j.1467-2494.2006.00349.x
– volume: 20
  year: 2019
  ident: B158
  article-title: Dysregulation of adenosinergic signaling in systemic and organ-specific autoimmunity.
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms20030528
– volume: 82
  start-page: 6
  year: 2014
  ident: B155
  article-title: TRR469, a potent A1 adenosine receptor allosteric modulator, exhibits antinociceptive properties in acute and neuropathic pain models in mice.
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2014.01.028
– volume: 12
  start-page: 728
  year: 2017
  ident: B112
  article-title: Neladenoson Bialanate hydrochloride: a prodrug of a partial adenosine A1 receptor agonist for the chronic treatment of heart diseases.
  publication-title: Chem. Med. Chem.
  doi: 10.1002/cmdc.201700151
– volume: 21
  start-page: 42
  year: 2013
  ident: B122
  article-title: Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications.
  publication-title: Cardiol. Rev.
  doi: 10.1097/CRD.0b013e3182613db6
– volume: 4
  year: 2016
  ident: B139
  article-title: Adenosine A2B receptor: from cell biology to human diseases.
  publication-title: Front. Chem.
  doi: 10.3389/fchem.2016.00037
– start-page: 499
  year: 2018
  ident: B7
  article-title: Adenosine Regulation of the Immune System
  publication-title: BT - The Adenosine Receptors
  doi: 10.1007/978-3-319-90808-3_20
– volume: 155
  start-page: 463
  year: 2008
  ident: B149
  article-title: Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions.
  publication-title: Br. J. Pharmacol.
  doi: 10.1038/bjp.2008.329
– volume: 15
  start-page: 931
  year: 2016
  ident: B39
  article-title: Treatment of plaque-type psoriasis with oral CF101: data from a phase II/III multicenter, randomized, controlled trial.
  publication-title: J. Drugs Dermatol.
– volume: 63
  start-page: 850
  year: 2014
  ident: B38
  article-title: A2B adenosine receptors prevent insulin resistance by inhibiting adipose tissue inflammation via maintaining alternative macrophage activation.
  publication-title: Diabetes
  doi: 10.2337/db13-0573
– volume: 57
  start-page: 440
  year: 2017
  ident: B157
  article-title: Safety and tolerability of Neladenoson Bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure.
  publication-title: J. Clin. Pharmacol.
  doi: 10.1002/jcph.828
– volume: 24
  start-page: 1631
  year: 2015
  ident: B97
  article-title: Discontinued neuropathic pain therapy between 2009–2015.
  publication-title: Exp. Opin. Invest. Drugs
  doi: 10.1517/13543784.2015.1099627
– volume: 8
  year: 2017
  ident: B148
  article-title: Purinergic receptors in adipose tissue as potential targets in metabolic disorders.
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2017.00878
– volume: 193
  start-page: 25
  year: 2009
  ident: B95
  article-title: A1 Adenosine receptor antagonists, agonists, and allosteric enhancers.
  publication-title: Handb. Exp. Pharmacol.
  doi: 10.1007/978-3-540-89615-9_2
– volume: 135
  start-page: 79
  year: 2017
  ident: B10
  article-title: Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism.
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2017.03.014
– volume: 24
  start-page: 59
  year: 2005
  ident: B130
  article-title: Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents.
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2004.09.010
– volume: 57
  start-page: 9901
  year: 2014
  ident: B144
  article-title: In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.
  publication-title: J. Med. Chem.
  doi: 10.1021/jm501021n
– volume: 558
  start-page: 559
  year: 2018
  ident: B42
  article-title: Structure of the adenosine-bound human adenosine A1 receptor–Gi complex.
  publication-title: Nature
  doi: 10.1038/s41586-018-0236-6
– volume: 13
  year: 2018
  ident: B101
  article-title: The A2B adenosine receptor in MDA-MB-231 breast cancer cells diminishes ERK1/2 phosphorylation by activation of MAPK-phosphatase-1.
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0202914
– volume: 58
  start-page: 296
  year: 2003
  ident: B121
  article-title: Robert Berne: his place in the history of purine research.
  publication-title: Drug Dev. Res.
  doi: 10.1002/ddr.10197
– volume: 18
  start-page: 25
  year: 2013
  ident: B138
  article-title: CF102 for the treatment of hepatocellular carcinoma: a phaseI/II, open- label, dose-escalation study.
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2012-0211
– volume: 172
  start-page: 68
  year: 2018
  ident: B44
  article-title: Allosteric coupling of drug binding and intracellular signaling in the A2A adenosine receptor.
  publication-title: Cell
  doi: 10.1016/j.cell.2017.12.004
– volume: 5
  start-page: 64
  year: 2004
  ident: B45
  article-title: Intrathecal but not intravenous opioids release adenosine from the spinal cord.
  publication-title: J. Pain
  doi: 10.1016/j.jpain.2003.10.001
– volume: 44
  start-page: 531
  year: 2001
  ident: B128
  article-title: Design, synthesis, and evaluation of novel A2A adenosine receptor agonists.
  publication-title: J. Med. Chem.
  doi: 10.1021/jm0003642
– volume: 135
  start-page: 2485
  year: 2017
  ident: B58
  article-title: Prospective study of adenosine on atrioventricular nodal conduction in pediatric and young adult patients after heart transplantation.
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.117.028087
– volume: 61
  start-page: 9966
  year: 2018
  ident: B75
  article-title: Preclinical evaluation of the first adenosine A1 receptor partial agonist radioligand for positron emission tomography (PET) imaging.
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01009
– volume: 91
  start-page: 25
  year: 2017
  ident: B78
  article-title: Structure-activity relationships of the sustained effects of adenosine A2A receptor agonists driven by slow dissociation kinetics.
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.116.105551
– volume: 1
  start-page: 1645
  year: 2017
  ident: B54
  article-title: Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease.
  publication-title: Blood Adv.
  doi: 10.1182/bloodadvances.2017009613
– volume: 111
  start-page: 904
  year: 2009
  ident: B48
  article-title: Adenosine: an old drug newly discovered.
  publication-title: Anesthesiology
  doi: 10.1097/ALN.0b013e3181b060f2
– year: 2011
  ident: B120
  publication-title: Short-Term Treatment of GS-9667 in Combination with Sitagliptin Improves Glucose and Lipid Homeostasis in ZDF rats.
– volume: 41
  start-page: 61
  year: 2001
  ident: B165
  article-title: Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers.
  publication-title: J. Clin. Pharmacol.
  doi: 10.1177/00912700122009845
– volume: 151
  start-page: 307
  year: 2018
  ident: B77
  article-title: Adenosine metabolism, immunity and joint health.
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2018.02.002
– volume: 3
  start-page: 55
  year: 2010
  ident: B110
  article-title: Design and application of locally delivered agonists of the adenosine A2A receptor.
  publication-title: Expert Rev. Clin. Pharmacol.
  doi: 10.1586/ecp.09.57
– volume: 2015
  year: 2015
  ident: B143
  article-title: Adenosine 2B receptor activation reduces myocardial reperfusion injury by promoting anti-inflammatory macrophages differentiation via PI3K/Akt pathway.
  publication-title: Oxid. Med. Cell. Longev.
  doi: 10.1155/2015/585297
– volume: 88
  start-page: 460
  year: 2015
  ident: B79
  article-title: A positive allosteric modulator of the adenosine A1 receptor selectively inhibits primary afferent synaptic transmission in a neuropathic pain model.
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.115.099499
– start-page: 91
  year: 2018
  ident: B11
  article-title: Chapter 5. A2A adenosine receptor: structures, modeling and medicinal chemistry
  publication-title: The Adenosine Receptors, The Receptors
  doi: 10.1007/978-3-319-90808-3_5
– volume: 17
  year: 2019
  ident: B163
  article-title: Physiology and effects of nucleosides in mice lacking all four adenosine receptors.
  publication-title: PLoS Biol.
  doi: 10.1371/journal.pbio.3000161
– volume: 8
  start-page: 57
  year: 2012
  ident: B124
  article-title: ATPaceTM: injectable adenosine 5′-triphosphate: diagnostic and therapeutic indications.
  publication-title: Purinergic Signal.
  doi: 10.1007/s11302-011-9268-1
– volume: 33
  start-page: 287
  year: 2008
  ident: B12
  article-title: The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways.
  publication-title: Int. J. Oncol.
– volume: 38
  start-page: 5
  year: 2018
  ident: B151
  article-title: Potential therapeutic applications of adenosine A2A receptor ligands and opportunities for A2A receptor imaging.
  publication-title: Med. Res. Rev.
  doi: 10.1002/med.21432
– volume: 99
  start-page: 1034
  year: 1999
  ident: B71
  article-title: Electrophysiologic effects of adenosine in patients with supraventricular tachycardia.
  publication-title: Circulation
  doi: 10.1161/01.CIR.99.8.1034
– year: 2013
  ident: B4
  article-title: A PK/PD study of a selective A2a agonist, (GW328267X) a potential IV therapeutic for acute lung injury: no tachyphylaxis to the heart rate effect. Abstract PC028.
  publication-title: Br. Pharmacol. Soc.
– volume: 186
  start-page: 4367
  year: 2011
  ident: B76
  article-title: Hypoxia-inducible factor-1α-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0903617
– volume: 90
  start-page: 297
  year: 2014
  ident: B63
  article-title: Probing biased/partial agonism at the G protein-coupled A2B adenosine receptor.
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2014.05.008
– volume: 8
  year: 2017
  ident: B66
  article-title: Purinergic signaling in mast cell degranulation and asthma.
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2017.00947
– volume: 8
  year: 2018
  ident: B113
  article-title: Structural basis for binding of allosteric drug leads in the adenosine A1 receptor.
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-35266-x
– volume: 21
  start-page: 965
  year: 2015
  ident: B140
  article-title: The Janus face of adenosine: antiarrhythmic and proarrhythmic actions.
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/1381612820666141029100346
– volume: 114
  start-page: 101
  year: 2017
  ident: B21
  article-title: Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms.
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2016.11.026
– volume: 8
  year: 2017
  ident: B136
  article-title: Pharmacological activity and clinical use of PDRN.
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2017.00224
– volume: 46
  start-page: 743
  year: 2018
  ident: B102
  article-title: Regulation of human brown adipose tissue by adenosine and A2A receptors – studies with [15O]H2O and [11C]TMSX PET/CT.
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-018-4120-2
– volume: 9
  year: 2014
  ident: B93
  article-title: The macrophage A2B adenosine receptor regulates tissue insulin sensitivity.
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0098775
– volume: 195
  year: 2016
  ident: B33
  article-title: CF602 improves erectile dysfunction in diabetic rats.
  publication-title: J. Urol.
  doi: 10.1016/j.juro.2016.02.2465
– volume: 37
  start-page: 419
  year: 2016
  ident: B16
  article-title: Adenosine as a multi-signalling guardian angel in human diseases: When, where and how does it exert its protective effects?
  publication-title: Trends Pharmacol. Sci.
  doi: 10.1016/j.tips.2016.02.006
– volume: 2018
  year: 2018
  ident: B31
  article-title: Inhibition of IL-17 and IL-23 in human keratinocytes by the A3 adenosine receptor agonist piclidenoson.
  publication-title: J. Immunol. Res.
  doi: 10.1155/2018/2310970
– start-page: 247
  year: 2017
  ident: B86
  article-title: Allosteric modulators of adenosine, P2Y and P2X receptors
  publication-title: Chapter
  doi: 10.1039/9781782629276
– volume: 356
  start-page: 474
  year: 2016
  ident: B22
  article-title: Peripheral adenosine A3 receptor activation causes regulated hypothermia in mice that is dependent on central histamine H1 receptors.
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.115.229872
– volume: 2
  start-page: 492
  year: 2009
  ident: B116
  article-title: Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma.
  publication-title: Circ. Cardiovasc. Imaging
  doi: 10.1161/CIRCIMAGING.108.817932
– volume: 16
  year: 2018
  ident: B68
  article-title: Marine alkylpurines: a promising group of bioactive marine natural products.
  publication-title: Mar. Drugs
  doi: 10.3390/md16010006
– year: 2012
  ident: B118
  article-title: The involvement of purinergic system in pain: adenosine receptors and inosine as pharmacological tools in future treatments
  publication-title: Chap. 28 in Pharmacology
– volume: 111
  start-page: 283
  year: 2016
  ident: B154
  article-title: Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety.
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2016.09.015
– volume: 32
  start-page: 534
  year: 2016
  ident: B84
  article-title: Ocular purine receptors as drug targets in the eye.
  publication-title: J. Ocular Pharmacol. Ther.
  doi: 10.1089/jop.2016.0090
– volume: 48
  start-page: 938
  year: 2015
  ident: B35
  article-title: Noninvasive characterization of atrioventricular conduction in patients with atrial fibrillation.
  publication-title: J. Electrocardiol.
  doi: 10.1016/j.jelectrocard.2015.08.010
– volume: 125
  start-page: 354
  year: 2012
  ident: B100
  article-title: A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.111.057596
– volume: 9
  year: 2018
  ident: B80
  article-title: Activation of A2A receptor by PDRN reduces neuronal damage and stimulates WNT/β-catenin driven neurogenesis in spinal cord injury.
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2018.00506
– volume: 8
  start-page: 91
  year: 2012
  ident: B2
  article-title: Partial adenosine A1 receptor agonists for cardiovascular therapies.
  publication-title: Purinergic Signal.
  doi: 10.1007/s11302-011-9274-3
– volume: 98
  start-page: 1591
  year: 2018
  ident: B18
  article-title: Pharmacology of adenosine receptors: the state of the art.
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.00049.2017
– volume: 10
  start-page: 465
  year: 2014
  ident: B107
  article-title: The role of activated adenosine receptors in degranulation of human LAD2 mast cells.
  publication-title: Purinergic Signal.
  doi: 10.1007/s11302-014-9409-4
– volume: 138
  start-page: 28
  year: 2015
  ident: B108
  article-title: Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states.
  publication-title: Brain
  doi: 10.1093/brain/awu330
– volume: 16
  start-page: 177
  year: 2016
  ident: B23
  article-title: Purinergic regulation of the immune system.
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2016.4
– volume: 11
  start-page: 371
  year: 2015
  ident: B145
  article-title: Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain.
  publication-title: Purinergic Signal.
  doi: 10.1007/s11302-015-9459-2
– volume: 230
  start-page: 2891
  year: 2015
  ident: B47
  article-title: The many faces of the A2b adenosine receptor in cardiovascular and metabolic diseases.
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.25043
– volume: 37
  start-page: 636
  year: 1994
  ident: B62
  article-title: Structure-activity relationships of N6-benzyladenosine-5(-uronamides as A3-selective adenosine agonists.
  publication-title: J. Med. Chem.
  doi: 10.1021/jm00031a014
– volume: 126
  start-page: 1717
  year: 2016
  ident: B96
  article-title: A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier.
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI76207
– volume: 163
  start-page: 21
  year: 2019
  ident: B160
  article-title: Ability of CP-532,903 to protect mouse hearts from ischemia/reperfusion injury is dependent on expression of A3 adenosine receptors in cardiomyoyctes.
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2019.01.022
– volume: 26
  start-page: 1855
  year: 2012
  ident: B26
  article-title: Controlling murine and rat chronic pain through A3 adenosine receptor activation.
  publication-title: FASEB J.
  doi: 10.1096/fj.11-201541
– volume: 8
  start-page: 48
  year: 2013
  ident: B29
  article-title: Dexmedetomidine: therapeutic use for the termination of reentrant supraventricular tachycardia.
  publication-title: Congenit. Heart Dis.
  doi: 10.1111/j.1747-0803.2012.00669.x
– volume: 1808
  start-page: 1319
  year: 2011
  ident: B115
  article-title: Adenosine receptor desensitization and trafficking.
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbamem.2010.06.007
– volume: 26
  start-page: 19
  year: 2002
  ident: B153
  article-title: Adenosine A2A receptor agonists pro- mote more rapid wound healing than recombinant human platelet- derived growth factor (Becaplermin gel).
  publication-title: Inflammation
  doi: 10.1023/A:1014417728325
– volume: 82
  start-page: 658
  year: 2011
  ident: B67
  article-title: Functionally biased modulation of A3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers.
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2011.06.017
– volume: 29
  start-page: 417
  year: 1997
  ident: B36
  article-title: Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats.
  publication-title: J. Cardiovasc. Pharmacol.
  doi: 10.1097/00005344-199703000-00017
– volume: 2
  start-page: 588
  year: 2009
  ident: B111
  article-title: New pharmacological agents for arrhythmias.
  publication-title: Circ. Arrhythm. Electrophysiol.
  doi: 10.1161/CIRCEP.109.884429
– volume: 6
  start-page: 899
  year: 2015
  ident: B92
  article-title: Translating drug-induced hibernation to therapeutic hypothermia.
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/acschemneuro.5b00056
– volume: 105
  start-page: 65
  year: 2013
  ident: B46
  article-title: Intrathecal, but not intravenous adenosine reduces allodynia in patients with neuropathic pain.
  publication-title: Pain
  doi: 10.1016/S0304-3959(03)00158-1
– volume: 175
  start-page: 4036
  year: 2018
  ident: B152
  article-title: New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism.
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.14337
– volume: 17
  start-page: 188
  year: 2011
  ident: B168
  article-title: Pain-relieving prospects for adenosine receptors and ectonucleotidases.
  publication-title: Trends Mol. Med.
  doi: 10.1016/j.molmed.2010.12.006
– volume: 42
  start-page: 3463
  year: 1999
  ident: B98
  article-title: N-Substituted adenosines as novel neuroprotective A1 agonists with diminished hypotensive effects.
  publication-title: J. Med. Chem.
  doi: 10.1021/jm960682u
– volume: 243
  start-page: 177
  year: 2017
  ident: B41
  article-title: Partial adenosine A1 agonist in heart failure.
  publication-title: Handb. Exp. Pharmacol.
  doi: 10.1007/164_2016_83
– volume: 97
  start-page: 215
  year: 2015
  ident: B52
  article-title: Metabolic mapping of A3 adenosine receptor agonist MRS5980.
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2015.07.007
– volume: 474
  start-page: 521
  year: 2011
  ident: B105
  article-title: Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.
  publication-title: Nature
  doi: 10.1038/nature10136
– volume: 11
  start-page: 251
  year: 2015
  ident: B126
  article-title: Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines.
  publication-title: Purinergic Signal.
  doi: 10.1007/s11302-015-9450-y
– volume: 19
  start-page: 126
  year: 2012
  ident: B167
  article-title: Selective adenosine agonists and myocardial perfusion imaging.
  publication-title: J. Nucl. Cardiol.
  doi: 10.1007/s12350-011-9474-9
– volume: 219
  start-page: 126
  year: 2009
  ident: B141
  article-title: Antiepileptic effects of silk-polymer based adenosine release in kindled rats.
  publication-title: Exp. Neurol.
  doi: 10.1016/j.expneurol.2009.05.018
– volume: 2014
  year: 2014
  ident: B30
  article-title: A3 adenosine receptor allosteric modulator induces an anti-inflammatory effect: In vivo studies and molecular mechanism of action.
  publication-title: Mediators Inflamm.
  doi: 10.1155/2014/708746
– year: 2019
  ident: B34
  article-title: Adenosine A3 receptor activation inhibits pro-nociceptive N-type Ca2+ currents in dorsal root ganglion neurons.
  publication-title: Pain
  doi: 10.1097/j.pain.0000000000001488
– volume: 39
  start-page: 2780
  year: 2018
  ident: B103
  article-title: Heart failure with preserved ejection fraction: from mechanisms to therapies.
  publication-title: Eur. Heart J.
  doi: 10.1093/eurheartj/ehy301
– volume: 128
  start-page: 1905
  year: 2005
  ident: B13
  article-title: Effects of aerosolized adenosine 5′-triphosphate vs adenosine 5′-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma.
  publication-title: Chest
  doi: 10.1378/chest.128.4.1905
– volume: 159
  start-page: 1025
  year: 2018
  ident: B159
  article-title: Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels via astrocyte-dependent mechanisms.
  publication-title: Pain
  doi: 10.1097/j.pain.0000000000001177
– volume: 21
  start-page: 155
  year: 2013
  ident: B51
  article-title: Comparison of the efficacy of topical minoxidil 5% and adenosine 0.75% solutions on male androgenetic alopecia and measuring patient satisfaction rate.
  publication-title: Acta Dermatovenerol. Croat.
– volume: 174
  start-page: 1945
  year: 2017
  ident: B17
  article-title: Pathological overproduction: the bad side of adenosine.
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.13763
– volume: 13
  start-page: 491
  year: 2019
  ident: B32
  article-title: Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy.
  publication-title: Drug Des. Dev. Ther.
  doi: 10.2147/DDDT.S195294
– volume: 31
  start-page: 1319
  year: 2010
  ident: B61
  article-title: Reversible coronary microvascular dysfunction: a common pathogenetic mechanism in apical ballooning or tako-tsubo syndrome.
  publication-title: Eur. Heart J.
  doi: 10.1093/eurheartj/ehq039
– volume: 151
  start-page: 201
  year: 2018
  ident: B65
  article-title: On the G protein-coupling selectivity of the native A2B adenosine receptor.
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2017.12.003
– volume: 53
  start-page: 385
  year: 2013
  ident: B137
  article-title: Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A1 adenosine receptor partial agonist.
  publication-title: J. Clin. Pharmacol.
  doi: 10.1002/jcph.9
– volume: 83
  start-page: 127
  year: 2000
  ident: B27
  article-title: Activation of adenosine A1 receptors by drugs to lower plasma glucose in streptozotocin-induced diabetic rats.
  publication-title: Auton. Neurosci.
  doi: 10.1016/S0165-1838(00)00106-5
– volume: 62
  start-page: 1502
  year: 2019
  ident: B147
  article-title: Design and in vivo characterization of A1 adenosine receptor agonists in the native ribose and conformationally-constrained (N)-methanocarba series.
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01662
– volume: 87
  start-page: 549
  year: 2015
  ident: B133
  article-title: Increased signaling via adenosine A1 receptors, sleep deprivation, imipramine, and ketamine inhibit depressive-like behavior via induction of homer1a.
  publication-title: Neuron
  doi: 10.1016/j.neuron.2015.07.010
– volume: 33
  start-page: 247
  year: 2017
  ident: B106
  article-title: Adenosine-guided radiofrequency catheter ablation of atrial fibrillation: a meta-analysis of randomized control trials.
  publication-title: J. Arrhythm.
  doi: 10.1016/j.joa.2017.02.002
– volume: 17
  start-page: 1901
  year: 2008
  ident: B50
  article-title: A1 adenosine receptor agonists and their potential therapeutic applications.
  publication-title: Expert Opin. Invest. Drugs
  doi: 10.1517/13543780802497284
– volume: 314
  start-page: 1792
  year: 2006
  ident: B25
  article-title: ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors.
  publication-title: Science
  doi: 10.1126/science.1132559
– volume: 10
  start-page: 529
  year: 2014
  ident: B19
  article-title: Purinergic signalling and immune cells.
  publication-title: Purinergic Signal.
  doi: 10.1007/s11302-014-9427-2
– volume: 179
  start-page: 2042
  year: 2011
  ident: B28
  article-title: A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats.
  publication-title: Am. J. Pathol.
  doi: 10.1016/j.ajpath.2011.07.006
– volume: 46
  start-page: 353
  year: 2003
  ident: B40
  article-title: 3′-Aminoadenosine-5′-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor.
  publication-title: J. Med. Chem.
  doi: 10.1021/jm0255724
– volume: 23
  start-page: 1109
  year: 2013
  ident: B70
  article-title: Adenosine A1 modulators: a patent update (2008 to present).
  publication-title: Expert Opin. Ther. Pat.
  doi: 10.1517/13543776.2013.799142
– volume: 55
  start-page: 62
  year: 2017
  ident: B123
  article-title: Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications.
  publication-title: Mol. Aspects Med.
  doi: 10.1016/j.mam.2016.12.001
– volume: 22
  start-page: 783
  year: 1972
  ident: B131
  article-title: Clinical-pharmacological studies with a new orally active adenosine derivative.
  publication-title: Drug Res.
– volume: 65
  start-page: 1675
  year: 2003
  ident: B64
  article-title: N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors.
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/S0006-2952(03)00153-9
– volume: 293
  start-page: 3685
  year: 2007
  ident: B166
  article-title: Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury.
  publication-title: Am. J. Physiol. Heart Circ. Physiol.
  doi: 10.1152/ajpheart.00819.2007
– volume: 36
  start-page: 3
  year: 2009
  ident: B94
  article-title: Synthesis and characterization of [76Br]-labeled high affinity A3 adenosine receptor ligands for positron emission tomography.
  publication-title: Nucl. Med. Biol.
  doi: 10.1016/j.nucmedbio.2008.10.003
– start-page: 3
  year: 2010
  ident: B59
  article-title: From hypertension (+) to asthma: interactions with the adenosine A3 receptor from a personal perspective
  publication-title: A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics
  doi: 10.1007/978-90-481-3144-0_1
– volume: 17
  start-page: 13712
  year: 2012
  ident: B109
  article-title: 5′-Chloro-5′-deoxy-( ± )-ENBA, a potent and selective adenosine A1 receptor agonist, alleviates neuropathic pain in mice through functional glial and microglial changes without affecting motor or cardiovascular functions.
  publication-title: Molecules
  doi: 10.3390/molecules171213712
– volume: 276
  start-page: 121
  year: 2017
  ident: B3
  article-title: The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets.
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12528
– volume: 101
  start-page: 585
  year: 2012
  ident: B142
  article-title: The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina.
  publication-title: Clin. Res. Cardiol.
  doi: 10.1007/s00392-012-0430-8
– volume: 65
  start-page: 906
  year: 2013
  ident: B15
  article-title: Adenosine kinase: exploitation for therapeutic gain.
  publication-title: Pharmacol. Rev.
  doi: 10.1124/pr.112.006361
– volume: 173
  start-page: 1253
  year: 2016
  ident: B90
  article-title: Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.13446
– year: 2018
  ident: B99
  publication-title: Compounds and Methods for Treating Neurological and Cardiovascular Conditions.
– volume: 55
  start-page: 8075
  year: 2012
  ident: B146
  article-title: Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity.
  publication-title: J. Med. Chem.
  doi: 10.1021/jm300965a
– volume: 11
  start-page: 389
  year: 2015
  ident: B5
  article-title: Selectivity is species-dependent: characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.
  publication-title: Purinergic Signal.
  doi: 10.1007/s11302-015-9460-9
– volume: 198
  start-page: 783
  year: 2003
  ident: B49
  article-title: Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in post-hypoxic endothelium: role of ectonucleotidases and adenosine A2B-receptors.
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20030891
– volume: 17
  start-page: 359
  year: 2012
  ident: B56
  article-title: Pharmacological and therapeutic effects of A3 adenosine receptor (A3AR) agonists.
  publication-title: Drug Discov. Today
  doi: 10.1016/j.drudis.2011.10.007
– volume: 39
  start-page: 3
  year: 1998
  ident: B81
  article-title: Hypoglycemic and hypotensive effects of 6-cyclohexyl-2′-O-methyl-adenosine, an adenosine A1 receptor agonist, in spontaneous hypertensive rat complicated with hyperglycemia.
  publication-title: Diabetes Res. Clin. Pract.
  doi: 10.1016/S0168-8227(97)00116-2
– volume: 14
  start-page: 59
  year: 2018
  ident: B43
  article-title: Species differences and mechanism of action of A3 adenosine receptor allosteric modulators.
  publication-title: Purinergic Signal.
  doi: 10.1007/s11302-017-9592-1
– volume: 38
  start-page: 1031
  year: 2018
  ident: B89
  article-title: A3 adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy.
  publication-title: Med. Res. Rev.
  doi: 10.1002/med.21456
– volume: 150
  start-page: 908
  year: 2016
  ident: B125
  article-title: Extracellular adenosine 5′-triphosphate in obstructive airway diseases.
  publication-title: Chest
  doi: 10.1016/j.chest.2016.06.045
– volume: 139
  start-page: 268
  year: 2018
  ident: B20
  article-title: Activation of adenosine A2A or A2B receptors causes hypothermia in mice.
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2018.02.035
– volume: 21
  start-page: 95
  year: 2016
  ident: B73
  article-title: Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.
  publication-title: Heart Fail. Rev.
  doi: 10.1007/s10741-015-9522-7
– volume: 151
  start-page: 129
  year: 2001
  ident: B88
  article-title: P1 and P2 purine and pyrimidine receptors.
  publication-title: Handb. Exp. Pharmacol.
– volume: 347
  start-page: 1
  year: 1998
  ident: B129
  article-title: Adenosine receptor activation and nociception.
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/S0014-2999(97)01605-1
– year: 2004
  ident: B14
  article-title: Aventis Pharma Deutschland. Novel Adenosine Analoguexs and their use as Pharmaceutical Agents.
– volume: 12
  start-page: 265
  year: 2013
  ident: B24
  article-title: Adenosine receptors as drug targets - What are the challenges?
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd3955
– volume: 30
  start-page: 42
  year: 2014
  ident: B162
  article-title: The elevated gene expression level of the A2B adenosine receptor is associated with hyperglycemia in women with gestational diabetes mellitus.
  publication-title: Diabetes Metab. Res. Rev.
  doi: 10.1002/dmrr.2446
– volume: 7
  year: 2018
  ident: B69
  article-title: Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein.
  publication-title: Elife
  doi: 10.7554/eLife.35946
– volume: 5
  start-page: 247
  year: 2006
  ident: B85
  article-title: Adenosine receptors as therapeutic targets.
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd1983
– volume: 28
  start-page: 287
  year: 2014
  ident: B55
  article-title: The role of adenosine signaling in sickle cell therapeutics.
  publication-title: Hematol. Oncol. Clin. North Am.
  doi: 10.1016/j.hoc.2013.11.003
– volume: 48
  start-page: 8103
  year: 2005
  ident: B87
  article-title: Semirational design of (N)-methanocarba nucleosides as dual acting A1 and A3 adenosine receptor agonists: novel prototypes for cardioprotection.
  publication-title: J. Med. Chem.
  doi: 10.1021/jm050726b
– volume: 66
  start-page: 360
  year: 2017
  ident: B82
  article-title: Increased airway hyperresponsiveness to adenosine in patients with aspirin intolerant asthma.
  publication-title: Allergol. Int.
  doi: 10.1016/j.alit.2016.10.001
– volume: 5
  year: 2008
  ident: B74
  article-title: The reno-vascular A2B adenosine receptor protects the kidney from ischemia.
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.0050137
– volume: 32
  start-page: 555
  year: 2016
  ident: B117
  article-title: A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily ocular trabodenoson in adults with ocular hypertension or primary open-angle glaucoma.
  publication-title: J. Ocul. Pharmacol. Ther.
  doi: 10.1089/jop.2015.0148
– volume: 13
  start-page: 41
  year: 2017
  ident: B37
  article-title: Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.
  publication-title: Nat. Rev. Rheumatol.
  doi: 10.1038/nrrheum.2016.178
– volume: 9
  start-page: 129
  year: 2014
  ident: B72
  article-title: Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.
  publication-title: Int. J. Chron. Obstruct. Pulmon. Dis.
  doi: 10.2147/COPD.S56879
– volume: 22
  start-page: 593
  year: 1972
  ident: B132
  article-title: Effect of repeated doses of phenylisopropyladenosine on lipid and carbohydrate metabolism in healthy fasting subjects.
  publication-title: Arzneim. Forsch.
– volume: 67
  start-page: 1138
  year: 1972
  ident: B161
  article-title: Zur Behandlung der Glomerulonephritis mit Metrifudil.
  publication-title: Medizinische Klinik
– volume: 23
  start-page: 431
  year: 2003
  ident: B53
  article-title: Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration.
  publication-title: Cell Mol. Neurobiol.
  doi: 10.1023/A:1023601007518
– volume: 11
  start-page: 175
  year: 2004
  ident: B134
  article-title: Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects.
  publication-title: Am. J. Ther.
  doi: 10.1097/00045391-200405000-00005
– volume: 116
  year: 2010
  ident: B127
  article-title: ATL313, a potent, and selective A2A agonist as a novel drug candidate for the treatment of multiple myeloma.
  publication-title: Blood
  doi: 10.1182/blood.V116.21.2990.2990
– volume: 68
  year: 2018
  ident: B57
  article-title: The anti-inflammatory and anto-fibrogenic effects of namodenoson in NAFLD/NASH animal models. Abstract Thu-487.
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(18)30921-8
– volume: 11
  start-page: 228
  year: 2015
  ident: B6
  article-title: Adenosine signalling in diabetes mellitus–pathophysiology and therapeutic considerations.
  publication-title: Nat. Rev. Endocrinol.
  doi: 10.1038/nrendo.2015.10
– volume: 12
  year: 2017
  ident: B91
  article-title: Adenosine for postoperative analgesia: a systematic review and meta-analysis.
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0173518
– volume: 117
  start-page: 1287
  year: 2010
  ident: B9
  article-title: Treatment of dry eye syndrome with orally-administered CF101: data from a Phase 2 clinical trial.
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2009.11.029
– volume: 38
  start-page: 2036
  year: 2015
  ident: B114
  article-title: Promotion of wound healing by an agonist of adenosine A2A Receptor is dependent on tissue plasminogen activator.
  publication-title: Inflammation
  doi: 10.1007/s10753-015-0184-3
– volume: 367
  start-page: 157
  year: 1999
  ident: B156
  article-title: Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects.
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/S0014-2999(98)00977-7
– volume: 15
  year: 2018
  ident: B83
  article-title: The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.
  publication-title: Fluids Barriers CNS
  doi: 10.1186/s12987-017-0088-8
– volume: 53
  start-page: 527
  year: 2001
  ident: B60
  article-title: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.
  publication-title: Pharmacol. Rev.
– volume: 232
  start-page: 442
  year: 2018
  ident: B119
  article-title: Infarct-sparing effect of adenosine A2B receptor agonist is primarily due to its action on splenic leukocytes via a PI3K/Akt/IL-10 pathway.
  publication-title: J. Surg. Res.
  doi: 10.1016/j.jss.2018.06.042
SSID ssj0062648
Score 2.5442183
SecondaryResourceType review_article
Snippet Adenosine receptors (ARs) function in the body's response to conditions of pathology and stress associated with a functional imbalance, such as in the supply...
Adenosine receptors (ARs) function in the body’s response to conditions of pathology and stress associated with a functional imbalance, such as in the supply...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 124
SubjectTerms Adenosine
Adenosine receptors
Agonists
Allosteric properties
Angina
Antagonists
Cardiac muscle
Clinical trials
CNS
Diabetes
Diabetes mellitus
Gene expression
Heart
Heart rate
Hypoxia
inflammation
Ischemia
Kinases
Neuroscience
Nutrients
Pain
purinergic signaling
Receptor mechanisms
Sickle cell disease
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5CDiWX0kfaukmDArnkYNZ62j5uS0MoJPTQQOhF6OU2ULyh2fz_zEjezW4p7SW39Xps5M8j6RvP6BPAifBGuCF0tcHZtFYy-drJwGtp3KC8Tq3z9EH_4tKcX6kv1_p6Y6svqgkr8sAFuFlwJkqZIkZSTkWnnTOt8nh_p6MRIi_zxTlvFUyVMdhQ3VZJSmII1s8GBJDyDDyLUwq1NQllrf6_Ecw_6yQ3Jp6zF_B8YoxsXlr6EnbS-AqeXUw58dfw_VHpg7kxsklxic0j6YCjCUNqmG7RhM1_LEgo947djOwrDnXTqshy2epgo4xoH67OPn_7dF5POybUQWuzrHHUo_hExLan9GASLuDjRsODcBphU0aHtpODFh13shGD7r1pArKA6NNgBvkGdsfFmN4BC0hFQucDMp5e4c--jyqKph0Mjw3vQgWzFYQ2THLitKvFL4thBYFuM-iWQLcZ9ApO11fcFimNf9h-pLeytiMR7PwHuoadXMP-zzUqOFy9Uzv1zDsr8mJdg5FuBcfr09inKFHixrS4JxteMt28grfFBdYtkU3fEYeroN1yjq2mbp8Zb35m3W6knq3h_P1TPNsB7BFaVA0nukPYXf6-Tx-QHi39Ue4JDzTBD28
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS91AEB5ahdIX6b2xWlLoSx_CyV6TPJVjUaSgSKkgfVn2FiuU5Og5_n9nks3RU8S3XCawOzs7-83O5FuAr9xpbltfFxpX00KK6AorPCuEtq10KlbW0Yb-yak-Ppc_L9RF2nBbprLKyScOjjr0nvbIZ3z4yVJjhPJ9cV3QqVGUXU1HaDyHbXTBNVr49sHh6dmvyRdrqt8ak5MYijWzFhVJ-QY2kFRyubEYDZz9jwHN_-slHyxAR69gJyHHfD4O9Wt4Frs38OIk5cbfwp97xo_cdiFPzEv5PBAfOIrkCBHjAkXy-WVPhLnL_KrLz9Dlpb8jx8-mmwflRO_g_Ojw94_jIp2cUHil9KpA70dxCg9VQ2nCyK3H7gbNPLeqkk5q5atatIrXzIqSt6pxuvSIBoKLrW7Fe9jq-i5-hNwjJPG184h8GomXTRNk4GXVahZKVvsMZpMKjU-04nS6xT-D4QUp3QxKN6R0Myg9g2_rLxYjpcYTsgc0Kms5IsMeHvQ3lybNLeOtDkLEgMG2lcEqazX2EU3QqqDRbjLYm8bUpBm6NPf2lMGX9WucW5QwsV3sb0mGjRlvlsGH0QTWLRFlUxOWy6DaMI6Npm6-6a7-DvzdCEErzdju0836BC9JD1Tvxus92Frd3MZ9BEAr9zlZ-R3P0Acd
  priority: 102
  providerName: ProQuest
Title Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
URI https://www.ncbi.nlm.nih.gov/pubmed/30983976
https://www.proquest.com/docview/2282516210
https://www.proquest.com/docview/2210004461
https://pubmed.ncbi.nlm.nih.gov/PMC6447611
https://doaj.org/article/ca6d33ed383a4da5aa674b2afa5d6228
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7aBEIuoe86TRcXeunBjfW0fShlE5KGwoZQurD0ImRJTgPBm2w2kP77zviVbFh66MXY1gik0Ugzoxl9AvjIS81t5fJEozZNpAhlYoVjidC2kqUKmS1pQ39yqk-m8vtMze6PR3cMvFnr2tF9UtPF5ee76z9fccJ_IY8T9e1-heyhKAJroCe5fAqbqJcyushhIoeYgqZcrjZQubbWNmyJtMhJP6_oqAbKf539-TiN8oFeOn4GO51BGY9bCXgOT0L9ArYmXcj8Jfy6BwKJbe3jDpApHnuCCUeSGC3HcIUk8fh8Tji6N_FFHZ_hStgdmmyr9R8PsoxewfT46OfhSdJdqJA4pfQywUWR3Bfus4Kih4Fbhz33mjluVSZLqZXLclEpnjMrUl6potSpQyPBl6HSlXgNG_W8Dm8hdmipuLx0aBAVEl-LwkvP06zSzKcsdxHs9yw0rkMbp0svLg16HcR_0_DfEP9Nw_8IPg01rlqkjX_QHtCoDHSEkd38mC_OTTfljLPaCxE8-uBWequs1dhHlEyrvOY8j2CvH1PTy53hzVlejY5wBB-GYpxyFEexdZjfEg1rA-EsgjetCAwt6UUogmxFOFaaulpSX_xuYL3RMs00Y7v_XfMdbBOLKEOO53uwsVzchvdoMi3LEWweHJ2e_Rg1Ww74_DZjo2Z2_AUkcho9
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVAIuiDeGAkaCAwcr3qftA0IptEppE1WolSou7np3XSpVdtqkQvwpfiMzfqQNQr31lsTjaD07O_uNZ_YbgPe80NyUNo007qaRFL6IjLAsEtqUslA-MQW90J9M9fhQfjtSR2vwpz8LQ2WVvU9sHLWrLb0jH_LmkKXGCOXz7DyirlGUXe1baLRmset__8KQbf5p5yvO7wfOt7cOvoyjrqtAZJXSiwg9A2F47pKMUmieG4tO2mlmuVGJLKRWNklFqXjKjIh5qbJCxxZ3Slf4UpcC__cOrEuBDzeA9c2t6f733vdrqhdrk6EY-mXDEieO8husIcXkcmXza3oE_A_Y_lufeW3D234IDzqkGo5a03oEa756DHcnXS7-Cfy4YhgJTeXCjukpHDniH0eRECGpn6FIODqpiaB3Hp5W4T662O40Zntb_-Va-dJTOLwVnT6DQVVX_gWEFiGQTQuLSCuT-DHLnHQ8TkrNXMxSG8CwV2FuOxpz6qZxlmM4Q0rPG6XnpPS8UXoAH5d3zFoKjxtkN2lWlnJEvt38UF-c5N1azq3RTgjvMLg30hlljMZnRJM3ymm00wA2-jnNO48wz6_sN4B3y8u4lilBYypfX5IMazPsLIDnrQksRyLiLCXsGECyYhwrQ129Up3-bPjCEfImmrGXNw_rLdwbH0z28r2d6e4ruE86oVo7nm7AYHFx6V8j-FoUbzqLD-H4thfZX7srQdg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9QwDLfGTZp4QXxTGBAkeOChukvapO0DQje208bY6YSYNPES0iQdk1B77G5C_Gv8ddhtetshtLe99cOtUsexndr-GeC1KJUwlc1jhdY0ThNfxiaxPE6UqdJS-syU9EP_aKr2j9OPJ_JkA_70tTCUVtnrxFZRu8bSP_KhaIssFVWcVCEtYrY7eT__GVMHKYq09u00OhE59L9_4fZt8e5gF-f6jRCTvS8f9uPQYSC2UqpljFqC_HnhsoLCaV4YiwrbKW6FkVlapkraLE8qKXJukpGoZFGqkUWr6UpfqSrB996CzYzKRwewubM3nX3u7YCi3LEuMIrbwGJY4SRSrIO3AJkiXTOEbb-A_zm5_-ZqXjF-k7twJ3itbNyJ2T3Y8PV92DoKcfkH8PUSbYSZ2rGA-sTGjrDIkYShe-rnSMLGpw2B9S7YWc1mqG5DZWb3WH9yJZXpIRzfCE8fwaBuav8EmEV3yOalRa-rSPGwKFzqxCirFHcjntsIhj0LtQ2Q5tRZ44fGrQ0xXbdM18R03TI9grerJ-YdnMc1tDs0Kys6AuJuLzTnpzqsa22NckniHW70TeqMNEbhN6L4G-kUymwE2_2c6qAdFvpSliN4tbqN65qCNab2zQXR8C7aziN43InAaiTJqMjJj4wgWxOOtaGu36nPvrfY4ej-Zorzp9cP6yVs4eLSnw6mh8_gNrGE0u5Evg2D5fmFf45-2LJ8EQSewbebXmN_AckPRhY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Historical+and+Current+Adenosine+Receptor+Agonists+in+Preclinical+and+Clinical+Development&rft.jtitle=Frontiers+in+cellular+neuroscience&rft.au=Jacobson%2C+Kenneth+A.&rft.au=Tosh%2C+Dilip+K.&rft.au=Jain%2C+Shanu&rft.au=Gao%2C+Zhan-Guo&rft.date=2019-03-28&rft.pub=Frontiers+Media+S.A&rft.eissn=1662-5102&rft.volume=13&rft_id=info:doi/10.3389%2Ffncel.2019.00124&rft_id=info%3Apmid%2F30983976&rft.externalDocID=PMC6447611
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1662-5102&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1662-5102&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1662-5102&client=summon